By using the body’s immune system, ITUS Corporation is taking multiple approaches to fighting cancer—developing both diagnostics and therapeutics to detect cancer early, when it is most curable, and to treat those afflicted once diagnosed.
Diagnostics
We are developing the Cchek™ platform, a series of inexpensive non-invasive blood tests for the early detection of solid tumors, which is based on the body’s immune response to the presence of a malignancy.
Therapeutics
We are developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs which genetically engineer a patient’s own immune cells to fight cancer.
Latest News & Events
Moffitt Cancer Center and ITUS Corporation Announce Scheduling of Pre-IND Meeting with the FDA for their CAR-T Therapy
Read More...ITUS Corporation to Present at Next Generation Dx Summit
Read More...Moffitt Cancer Center and ITUS Corporation Request Meeting with FDA Regarding Ovarian Cancer CAR-T Therapy
Read More...Cancer of the Lung, Breast, Colon, Prostate, and Stomach are the five most prevalent cancers worldwide.